Research Progress on Tumor Necrosis Factor-α and Its Inhibitors in the Field of Reproduction

doi:10.12280/gjszjk.20250025

Abstract

Abstract:

Tumor necrosis factor-α (TNF-α) as a pro-inflammatory factor plays an important role in the pathogenesis of reproductive disease. The overexpression of TNF-α can induce recurrent spontaneous abortion, polycystic ovary syndrome, endometriosis and others, which eventually lead to adverse pregnancy outcomes. In recent years, with the development of TNF-α research, TNF-α inhibitors have gradually entered the clinical field of vision, providing a new direction for the treatment of reproductive diseases. Studies have shown that TNF-α inhibitors can inhibit the biological activity of TNF-α by blocking its binding to its receptor, thereby reducing the inflammation response and the over activation of the immune system. Thus, TNF-α inhibitors have been shown the potential therapeutic value in a variety of reproductive diseases such as recurrent spontaneous abortion, polycystic ovary syndrome, and endometriosis. However, the current research on its efficacy, safety and potential risks is still at the exploratory stage and further research is needed.

Key words: Tumor necrosis factor-alpha, Tumor necrosis factor inhibitors, Abortion, habitual, Polycystic ovary syndrome, Endometriosis

LI Wen-an, FU Sheng-lan, HOU Zhi-jin, MENG Yu-shi. Research Progress on Tumor Necrosis Factor-α and Its Inhibitors in the Field of Reproduction[J]. Journal of International Reproductive Health/Family Planning, 2025, 44(3): 259-264.

References 31

[1]	Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, et al. Tumour necrosis factor signalling in health and disease[J]. F1000Res, 2019, 8:F1000 Faculty Rev-111. doi: 10.12688/f1000research.17023.1.
[2]	张婧元, 沈敏. TNF-α抑制剂治疗自身炎症性疾病的机制[J]. 中华临床免疫和变态反应杂志, 2023, 17(1):68-73. doi: 10.3969/j.issn.1673-8705.2023.01.013.
[3]	AbdulHussain G, Azizieh F, Makhseed M, et al. Effects of Progesterone, Dydrogesterone and Estrogen on the Production of Th1/Th2/Th17 Cytokines by Lymphocytes from Women with Recurrent Spontaneous Miscarriage[J]. J Reprod Immunol, 2020, 140:103132. doi: 10.1016/j.jri.2020.103132.
[4]	Murvai VR, Gali R, Panaitescu A, et al. Antiphospholipid syndrome in pregnancy: a comprehensive literature review[J]. BMC Pregnancy Childbirth, 2025, 25(1):337. doi: 10.1186/s12884-025-07471-w.
[5]	Álvarez D, Morales-Prieto DM, Cadavid ÁP. Interaction between endothelial cell-derived extracellular vesicles and monocytes: A potential link between vascular thrombosis and pregnancy-related morbidity in antiphospholipid syndrome[J]. Autoimmun Rev, 2023, 22(4):103274. doi: 10.1016/j.autrev.2023.103274.
[6]	Fonseca BM, Cunha SC, Gonçalves D, et al. Decidual NK cell-derived conditioned medium from miscarriages affects endometrial stromal cell de cidualisation: endocannabinoid anandamide and tumour necrosis factor-α crosstalk[J]. Hum Reprod, 2020, 35(2):265-274. doi: 10.1093/humrep/dez260.
[7]	Wu H, You Q, Jiang Y, et al. Tumor necrosis factor inhibitors as therapeutic agents for recurrent spontaneous abortion (Review)[J]. Mol Med Rep, 2021, 24(6):847. doi: 10.3892/mmr.2021.12487.
[8]	Zhong Z, Wang Y, Wang G, et al. Case Report: TNF-Alpha Inhibitors to Rescue Pregnancy in Women With Potential Pregnancy Loss: A Report of Ten Cases[J]. Front Immunol, 2022, 13:900537. doi: 10.3389/fimmu.2022.900537.
[9]	Mekinian A, Houfflin-Debarge V, Kolanska K, et al. Antagonists of TNFα for recurrent miscarriages: 2 Illustrative cases[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 236:263-264. doi: 10.1016/j.ejogrb.2019.02.036. pmid: 30872045
[10]	Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion[J]. Am J Reprod Immunol, 2008, 60(1):8-16. doi: 10.1111/j.1600-0897.2008.00585.x. pmid: 18422811
[11]	Fu J, Li L, Qi L, et al. A randomized controlled trial of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders[J]. Taiwan J Obstet Gynecol, 2019, 58(5):621-625. doi: 10.1016/j.tjog.2019.07.007. pmid: 31542082
[12]	Mizgier M, Jarzabek-Bielecka G, Wendland N, et al. Relation between Inflammation, Oxidative Stress, and Macronutrient Intakes in Normal and Excessive Body Weight Adolescent Girls with Clinical Features of Polycystic Ovary Syndrome[J]. Nutrients, 2021, 13(3):896. doi: 10.3390/nu13030896.
[13]	Ha LX, Wu YY, Yin T, et al. Effect of TNF-alpha on endometrial glucose transporter-4 expression in patients with polycystic ovary syndrome through nuclear factor-kappa B signaling pathway activation[J]. J Physiol Pharmacol, 2021, 72(6). doi: 10.26402/jpp.2021.6.13.
[14]	Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)--a novel theory for the development of Polycystic Ovarian Syndrome[J]. Med Hypotheses, 2012, 79(1):104-112. doi: 10.1016/j.mehy.2012.04.016. pmid: 22543078
[15]	Sadeghi HM, Adeli I, Calina D, et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing[J]. Int J Mol Sci, 2022, 23(2):583. doi: 10.3390/ijms23020583.
[16]	Utkan Korun ZE, Gocmez SS, Furat Rencber S, et al. Etanercept Ameliorates Vascular, Endocrine, and Ovarian Changes in a Rat Model of DHEA-Induced Polycystic Ovary Syndrome[J]. Reprod Sci, 2024, 31(3):714-726. doi: 10.1007/s43032-023-01392-9.
[17]	Liang JX, Zhang Y, Xiao CH, et al. Application value of tumor necrosis factor inhibitors in in vitro fertilization-embryo transfer in infertile women with polycystic ovary syndrome[J]. BMC Pregnancy Childbirth, 2023, 23(1):247. doi: 10.1186/s12884-023-05546-0.
[18]	Chowdhury I, Banerjee S, Driss A, et al. Curcumin attenuates proangiogenic and proinflammatory factors in human eutopic endometrial stromal cells through the NF-κB signaling pathway[J]. J Cell Physiol, 2019, 234(5):6298-6312. doi: 10.1002/jcp.27360. pmid: 30259980
[19]	温丽, 郭珍, 常春红, 等. 子宫内膜异位症患者血清和腹腔液中VEGF、IL-6、TNF-α、CA125表达及临床意义[J]. 现代中西医结合杂志, 2017, 26(5):467-470. doi: 10.3969/j.issn.1008-8849.2017.05.004.
[20]	Voltolini Velho R, Halben N, Chekerov R, et al. Functional changes of immune cells: signal of immune tolerance of the ectopic lesions in endometriosis?[J]. Reprod Biomed Online, 2021, 43(2):319-328. doi: 10.1016/j.rbmo.2021.04.012. pmid: 34103260
[21]	Guo B, Zhu H, Xiao C, et al. NLRC5 exerts anti-endometriosis effects through inhibiting ERβ-mediated inflammatory response[J]. BMC Med, 2024, 22(1):351. doi: 10.1186/s12916-024-03571-0. pmid: 39218863
[22]	Kaplan S, Kırıcı P, Türk A. The effects of adalimumab on the rat autotransplantation endometriosis model: A placebo-controlled randomized study[J]. Adv Clin Exp Med, 2022, 31(4):417-426. doi: 10.17219/acem/144369. pmid: 35040600
[23]	Önalan G, Tohma YA, Zeyneloglu HB. Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma[J]. Gynecol Obstet Invest, 2018, 83(4):358-364. doi: 10.1159/000484895. pmid: 29208847
[24]	Duricova D, Dvorakova E, Hradsky O, et al. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation[J]. Inflamm Bowel Dis, 2019, 25(4):789-796. doi: 10.1093/ibd/izy294. pmid: 30239799
[25]	Mirdamadi K, Salinas T, Vali R, et al. Meta-Analysis of Pregnancy Outcomes after Exposure to TNF-α Inhibitors During Pregnancy for the Treatment of Arthritic Diseases[J]. J Popul Ther Clin Pharmacol, 2018, 25(1):e53-e56. doi: 10.22374/1710-6222.25.1.5.
[26]	Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases[J]. Arthritis Care Res(Hoboken), 2020, 72(4):461-488. doi: 10.1002/acr.24130.
[27]	Yüksek T, Ataᶊ H, Kartal SP, et al. Impact of adalimumab on erectile dysfunction, sperm parameters and hormonal profile in male psoriasis patients: a six-month observational study[J]. Arch Dermatol Res, 2024, 317(1):21. doi: 10.1007/s00403-024-03520-0.
[28]	Micu MC, Ostensen M, Bojincă V, et al. Pregnancy Outcomes in Couples with Males Exposed to Longterm Anti-tumor Necrosis Factor-α Inhibitor Therapies: A Prospective Study[J]. J Rheumatol, 2019, 46(9):1084-1088. doi: 10.3899/jrheum.180588.
[29]	Sartori NS, Picon P, Papke A, et al. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment[J]. PLoS One, 2019, 14(12):e0224963. doi: 10.1371/journal.pone.0224963.
[30]	D′Arcy ME, Beachler DC, Pfeiffer RM, et al. Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(11):2059-2067. doi: 10.1158/1055-9965.EPI-21-0125.
[31]	Geisen UM, Sümbül M, Tran F, et al. Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies[J]. RMD Open, 2021, 7(3):e002008. doi: 10.1136/rmdopen-2021-002008.